Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress

被引:1
|
作者
Liu, Yajun [1 ]
Li, Chenyao [2 ]
Liu, Hongwei [3 ,4 ]
Tan, Shutao [5 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Wenhua Rd 103, Shenyang 110016, Peoples R China
[2] Dalian Univ Technol, Sch Life & Pharmaceut Sci, Dagong Rd 2, Panjin 124221, Peoples R China
[3] Liaoning Canc Hosp & Inst, Dept Head & Neck Surg, Shenyang 110042, Peoples R China
[4] Dalian Univ Technol, Affiliated Canc Hosp, Shenyang 110042, Peoples R China
[5] China Med Univ, Dept Urol, Shengjing Hosp, Sanhao St 36, Shenyang 110004, Peoples R China
关键词
HSP90; inhibitors; Cancer therapy; Drug combination; Synergistic effect; Drug resistance; SHOCK-PROTEIN; 90; CELL LUNG-CANCER; I DOSE-ESCALATION; PHASE-I; OVERCOMES RESISTANCE; THYMIDYLATE SYNTHASE; ANTITUMOR-ACTIVITY; ONALESPIB AT13387; COLORECTAL-CANCER; DRUG-RESISTANCE;
D O I
10.1007/s12272-024-01494-1
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The molecular chaperone heat shock protein 90 (HSP90) regulates multiple crucial signalling pathways in cancer by driving the maturation of key signalling components, thereby playing a crucial role in tumorigenesis and drug resistance in cancer. Inhibition of HSP90 results in metastable conformational collapse of its client proteins and their proteasomal degradation. Considerable efforts have been devoted to the development of small-molecule inhibitors targeting HSP90, and more than 20 inhibitors have been evaluated in clinical trials for cancer therapy. However, owing to disadvantages such as organ toxicity and drug resistance, only one HSP90 inhibitor has been approved for use in clinical settings. In recent years, HSP90 inhibitors used in combination with other anti-cancer therapies have shown remarkable potential in the treatment of cancer. HSP90 inhibitors work synergistically with various anti-cancer therapies, including chemotherapy, targeted therapy, radiation therapy and immunotherapy. HSP90 inhibitors can improve the pharmacological effects of the above-mentioned therapies and reduce treatment resistance. This review provides an overview of the use of combination therapy with HSP90 inhibitors and other anti-cancer therapies in clinical and preclinical studies reported in the past decade and summarises design strategies and prospects for these combination therapies. Altogether, this review provides a theoretical basis for further research and application of these combination therapies in the treatment of cancer.
引用
收藏
页码:442 / 464
页数:23
相关论文
共 50 条
  • [41] Effectiveness of Hsp90 inhibitors as anti-cancer drugs
    Xiao, Li
    Lu, Xiangyi
    Ruden, Douglas M.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2006, 6 (10) : 1137 - 1143
  • [42] HSP90 Inhibitors in Lung Cancer: Promise Still Unfulfilled
    Chatterjee, Suman
    Bhattacharya, Saveri
    Socinski, Mark A.
    Burns, Timothy F.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (05) : 346 - 356
  • [43] Development of novel hsp90 inhibitors as cancer therapeutics.
    Chiosis, G
    Rosen, N
    Lucas, B
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U46 - U46
  • [44] Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo
    Levine, Ross L.
    Koppikar, Priya
    Marubayashi, Sachie
    Bhagwat, Neha
    Taldone, Tony
    Park, Christopher Y.
    Chiosis, Gabriela
    BLOOD, 2012, 120 (21)
  • [45] Hsp90 inhibition accelerates cell lysis -: Anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide- and Hsp90-dependent events
    Sreedhar, AS
    Mihály, K
    Pató, B
    Schnaider, T
    Steták, A
    Kis-Petik, K
    Fidy, J
    Simonics, T
    Maráz, A
    Csermely, P
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (37) : 35231 - 35240
  • [46] Recent progress and structural insights of potential Hsp90 inhibitors as anticancer agents
    Singh, Aastha
    Maity, Subhadip
    Devi, Priya
    Rai, Aman
    Asati, Vivek
    MOLECULAR DIVERSITY, 2025,
  • [47] Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate Cancer
    Kang, Byoung Heon
    Siegelin, Markus D.
    Plescia, Janet
    Raskett, Christopher M.
    Garlick, David S.
    Dohi, Takehiko
    Lian, Jane B.
    Stein, Gary S.
    Languino, Lucia R.
    Altieri, Dario C.
    CLINICAL CANCER RESEARCH, 2010, 16 (19) : 4779 - 4788
  • [48] HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy
    Lin, Tzu-yin
    Guo, Wenchang
    Long, Qilai
    Ma, Aihong
    Liu, Qiangqiang
    Zhang, Hongyong
    Huang, Yee
    Chandrasekaran, Siddarth
    Pan, Chongxian
    Lam, Kit S.
    Li, Yuanpei
    THERANOSTICS, 2016, 6 (09): : 1324 - 1335
  • [49] Human recombinant antibody to HSP90: A natural partner in combination therapy
    Matthews, RC
    Burnie, JP
    CURRENT MOLECULAR MEDICINE, 2005, 5 (04) : 403 - 411
  • [50] Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials
    Chang, Cheng
    Tang, Xin
    Woodley, David T.
    Chen, Mei
    Li, Wei
    CELL STRESS & CHAPERONES, 2024, 29 (05): : 642 - 653